Hims & Hers Health (NYSE: HIMS) to acquire YourBio Health to add patented, pain-free TAP and HALO blood sampling technology to its wellness platform The acquisition will integrate virtually painless microneedle blood collection into a broader direct‑to‑consumer health platform, enabling fast, high‑quality capillary sampling outside traditional clinics. Protected microtechnology around device design, sample handling, and integration supports future test expansion, while incoming scientific and executive leaders will steer development of more user‑friendly diagnostics after the all‑cash deal closes. (Link)
Overjet acquires Toledo AI startup DentalBee to combine voice-driven documentation with dental imaging in a unified clinical intelligence platform The transaction pairs real-time voice capture of periodontal measurements, notes, and referral details with AI analysis of X‑rays to create fully structured dental records while easing documentation burden for clinicians. It also underscores Northwest Ohio’s emergence as an AI hub, with regional economic development groups credited for helping the startup reach acquisition. (Link)
Joi + Blokes acquires HerMD to build a nationwide virtual women’s health platform for menopause, sexual health, and hormonal care The merger will expand access to longer virtual consults with hormone and menopause specialists, broader treatment options, and preventive lab support in every state, while adding research participation opportunities. HerMD’s education-first approach will drive new national learning initiatives as the combined platform works to deliver more consistent, empathetic, evidence-based care to underserved midlife women. (Link)
Lightbeam Health Solutions acquires Syntax Health to integrate value-based contracting and actuarial modelling into its AI-enabled population health platform The acquisition adds a contract‑modelling engine and actuarial talent into a broader value‑based care operating system, allowing payers and providers to rapidly simulate deals, align on assumptions, and project financial results with more confidence. By tying benchmarking and forecasting directly to contract design, the combined platform aims to reduce administrative complexity and refocus attention on population outcomes. (Link)
Avandra Health acquires DatCard Systems and Sorna Corporation to build a unified global medical imaging and clinical data platform for patient care and research The enlarged platform will connect distribution tools already embedded at thousands of sites with a federated, de‑identified imaging network, making it easier for hospitals to share studies and for life sciences partners to tap high‑value data. By investing in upgrades and support while preserving existing brands, the organization aims to unlock siloed imaging for both care and research. (Link)
Ciba Health partners with Quikcard to launch personalized, prevention‑first metabolic and chronic care programs for Canadians The partnership brings structured 12‑month programs with dietitian and health‑coach support, personalized plans, and continuous tracking to help members address metabolic risk and chronic conditions through lifestyle change rather than medication alone. Validated outcomes include meaningful HbA1c drops, sharply reduced overall drug use and costs, and GLP‑1 Step Down participants lowering GLP‑1 dependence while losing weight over six months. (Link)
XRHealth acquires Innerworld to build an immersive, stepped-care XR platform for mental health and rehabilitation The combined platform will pair always‑on, community‑based mental health support—via live events, facilitator‑led groups, and global peer interaction—with existing VR/AR treatments for pain, rehab, PTSD, stress, addiction, and OCD. By adding Innerworld’s founder as chief clinical officer and building on prior XR acquisitions, the company is constructing a stepped‑care, AI‑enhanced XR ecosystem spanning self‑help to clinician‑guided therapy. (Link)
Cerbo acquires OptiMantra, via its financial sponsors Search Fund Partners, Applied Equity Partners, Manifestations Capital, Hunter Search Capital, Endurance Search Partners, and Red Forest Capital to build AI-powered practice platform for specialty and integrative care The merger creates a single EMR and practice‑management platform for integrative, functional, direct primary care, concierge, behavioral health, and IV/injectable practices, targeting the operational needs of membership‑ and cash‑pay models. Backed by multiple financial sponsors, the combined team will co‑develop AI‑enabled workflows, CRM-driven growth tools, and upgraded payment capabilities while keeping founders engaged and a customer‑first culture intact. (Link)
BriteLife Recovery acquires Summit Behavioral Health to add intensive outpatient services to its East Coast addiction treatment network The deal extends care into flexible day and evening intensive outpatient programming at the Princeton Junction site, supported by transportation, alumni services, family recovery programming, and enhanced staff training. BriteLife’s broader network across several East Coast states, plus insurance acceptance and scholarships, is intended to make trauma‑informed, relationship‑centered treatment more accessible. (Link)
CQ Medical acquires Bionix Radiation Therapy business unit to expand global radiotherapy positioning and marking portfolio The acquisition brings additional radiotherapy accessories and a seasoned sales team under the same umbrella, broadening an existing suite of positioning, immobilization, and image‑guided treatment devices used in oncology. CQ Medical plans to absorb the new product lines into its current manufacturing footprint while Bionix redirects attention and investment to its remaining ambulatory care portfolio. (Link)
Natera (NASD: NTRA) acquires Foresight Diagnostics in up to $450 million deal to expand minimal residual disease cancer testing portfolio The transaction adds ultra‑sensitive PhasED‑Seq assays that can detect lymphoma relapse at very low circulating tumour DNA levels long before standard imaging, alongside a CLIA‑registered lab and lymphoma expertise that deepen the existing MRD offering. It follows settlement of past IP disputes and comes amid strong cancer testing growth but continued net losses. (Link)
Paradigm Health raises $78 million Series B from ARCH Venture Partners, DFJ Growth, F-Prime, General Catalyst, GV, Lux Capital, Mubadala Capital, and American Cancer Society’s BrightEdge Fund to expand AI-enabled clinical trial infrastructure The platform links biopharma sponsors with 166 provider organizations and 2,100 care sites across 45 states. Automated matching and site-feasibility tools let health systems enrol up to four times faster and reduce clinician burden, while a new design service embeds interventional and pragmatic trials directly into routine workflows and expands into neuroscience, cardiovascular, and metabolic research. (Link)
Artera raises $65 million from Lead Edge Capital, Jackson Square Ventures, Health Velocity Capital, Heritage Medical Systems, and Summation Health Ventures to scale agentic AI for patient communication The company is using a decade of real‑world communication data to train AI that automates routine scheduling, intake, billing, and messaging across more than 1,000 provider organizations and 2 billion yearly interactions. Its “flow agents” already handle most exchanges without staff, while co‑pilot tools summarize, translate, and surface priority outreach, saving substantial administrative time. (Link)
Curi Bio raises $10 million Series B led by DreamCIS to scale human iPSC-based preclinical platforms and advanced functional data analysis for drug discovery Curi Bio is expanding a platform that uses high‑purity human iPSC‑derived cells, tissue‑specific 3D biosystems, and rich functional data to predict human drug responses more accurately than animal or 2D models. These assays guide candidate selection and IND decisions across multiple diseases, while partner DreamCIS contributes clinical research and regulatory expertise to boost trial success. (Link)
Lyric Bio, Inc. raises $6.6 million seed round led by The Venture Collective, with Black Diamond Ventures, Draper Associates, Lucas Venture Group, Meiji Seika Pharma, SOSV, and others to advance donor‑derived therapeutics biomanufacturing Lyric Bio is building ultra‑high‑density 3D bioreactors that mimic human tissue to manufacture donor‑derived therapies at scale, starting with IVIg and SCIg in a $20 billion market. By targeting up to 100x efficiency gains, the team aims to slash costs, cut reliance on human donors, and deliver more consistent, accessible immunoglobulin products. (Link)
Patient Square Capital completes $2.6 billion take-private acquisition of Premier, Inc (NASD: PINC), paying $28.25 per share in all-cash deal. The deal takes Premier private and keeps its operations focused on powering healthcare improvement through analytics, supply chain offerings, collaboratives, and advisory services. As part of a larger healthcare-focused portfolio, the company is expected to use additional capital and expertise to enhance technology-driven tools that help providers improve outcomes and reduce costs. (Link)
Bruker Corporation (NASD: BRKR) acquires AST Revolution to advance WAVE and Arc rapid antimicrobial susceptibility testing technologies and expand clinical diagnostics portfolio The deal shifts a revitalized rapid testing platform into a larger diagnostics ecosystem, keeping focus on delivering quicker, clinically actionable antimicrobial susceptibility results. With prior investment having stabilized and advanced the WAVE and Arc systems, the new owner is expected to use its scale, market access, and technical depth to speed adoption in laboratories and hospitals. (Link)
MDI NetworX acquires Cobalt MedPlans (Clarity Performance Solutions) from Cobalt Health Solutions, a Blue Cross and Blue Shield of Kansas City Subsidiary, to Expand U.S. Payer Services and Deploy InsightPro AI Platform The deal adds 250 U.S. staff and two Kansas delivery centers, lifting the company’s global workforce above 7,500 and growing its domestic operations to four sites. It plans to intensify investment in automation, analytics, and workforce capabilities to deliver scalable, end-to-end payer operations while tightening control of administrative costs. (Link)
US Fertility partners with L Catterton and Amulet Capital Partners in new co-lead investor structure to expand access to advanced reproductive care across the U.S. The updated ownership structure preserves significant physician ownership while adding growth capital and consumer-health expertise to scale US Fertility’s clinics, labs, and research programs. It supports broader access to IVF, IUI, genetic testing, and related services, while reinforcing a physician-led, patient-centered care model for tens of thousands of new patients annually. (Link)
MedEdge Holdings launches with $450 million management-led buyout to integrate Abyrx’s biomaterials portfolio and Kairuku’s surgical SaaS platform The holding company will merge biomaterials and surgical software capabilities to streamline product sourcing, inventory control, and case coordination for hospitals and OR teams. Profitable operations plus new capital will fund acquisitions of 10–15 commercial-stage products, aiming to cut administrative complexity while broadening access to next‑generation surgical technologies. (Link)
FluidAI Medical acquires Emmetros Limited, developer of SparxConnect, to strengthen AI-driven Stream Inara patient engagement The integration focuses on stronger postoperative monitoring and communication, using collaboration tools to guide patients before procedures and through home recovery. It supports earlier discharge while preserving visibility into outcomes and patient‑reported data, and complements existing monitoring, surgical decision support, and recovery programs to boost throughput, bed utilization, and personalized recovery planning. (Link)
Innova Therapeutics acquires Enci Therapeutics to advance IVT-8086, a first-in-class monoclonal antibody targeting SFRP2 in solid and hematologic cancers The deal centralizes control of IVT-8086 to accelerate its development as a targeted therapy against a key signalling pathway driving angiogenesis, tumour growth, immune evasion, and metastasis. Strong preclinical data support its potential both as monotherapy and in combination with checkpoint inhibitors, alongside a companion diagnostic to guide detection, prognosis, and relapse monitoring. (Link)
MiCare Path acquires Compwell, LLC to accelerate national expansion of AI-powered virtual care platform The platform now supports large, multispecialty patient panels with reimbursable programs for remote monitoring and ongoing care management. New capital and the Compwell integration will grow clinical services, deepen health system collaborations, and accelerate AI-driven workflow automation, enabling more proactive, personalized virtual care that extends clinician support into patients’ daily lives. (Link)
Brown’s Medical Imaging and Prestige Medical Imaging merge to expand nationwide, multi-vendor medical imaging service capabilities The merged business broadens nationwide coverage while maintaining a vendor-agnostic service model with strong uptime and response commitments. A 150‑plus engineer field force provides fast remote and onsite support, underpinned by a customer‑first, end‑to‑end service philosophy. Leadership promotions reinforce continuity and position the company for its next phase of growth. (Link)
AleraCare, backed by Hildred Capital Management, to merge with Pure Healthcare to Form National Platform for Ambulatory Infusion and Specialty Care The merged platform operates 77 infusion centers in 14 states, pairing complex-chronic-care expertise with expanding home and alternate-site services. A unified contracting and technology backbone supports payors, providers, and biopharma with faster therapy starts, better adherence, and AI-enabled scheduling, benefits checks, and real-time outcomes tracking, while maintaining a safety- and compassion-focused culture. (Link)
Abbott (NYSE: ABT) to acquire Exact Sciences (NASD: EXAS) in $21 Billion All-Cash Deal to Expand Global Cancer Screening and Precision Oncology Diagnostics Portfolio The deal will make Exact Sciences a subsidiary, helping Abbott reach $12 billion in diagnostics sales. Exact’s Madison, Wisconsin presence and leadership will remain, with the CEO advising during transition. Shareholder and regulatory approvals are expected before closing in mid-2026. (Link)
Merck (NYSE: MRK) to acquire Cidara Therapeutics (NASD: CDTX) for $9.2 Billion, Gaining Late-Phase Antiviral CD388 for Influenza Prevention After the deal’s approval, Cidara Therapeutics will strengthen Merck’s presence in antivirals with CD388 targeting high-risk influenza populations. The acquisition structure ensures all Cidara shares are purchased, pending regulatory clearance, with closing planned for the first quarter of 2026. (Link)
GE Healthcare (NASD: GEHC) to acquire Intelerad in $2.3 Billion Deal to Expand Cloud-Enabled and AI-Driven Imaging Platform for Radiology, Cardiology, and Outpatient Enterprise Markets The integration will modernize imaging workflows for outpatient and ambulatory care, leveraging Intelerad’s SaaS and AI strengths to streamline operations, unify data, and improve provider efficiency. Backed by global reach and financial flexibility, GE HealthCare expects significant recurring revenue and top-line growth from expanded cloud imaging offerings. (Link)
Solventum (NYSE: SOLV) to acquire Acera Surgical for $725 Million Plus Milestone Payments, Expanding Advanced Wound Care Portfolio with Synthetic Tissue Matrices Technology Acera’s Restrata product, a fully resorbable electrospun fiber matrix, treats hard-to-heal acute care wounds by supporting cellular growth and healing. Solventum will use its sales expertise and international presence to accelerate Restrata’s adoption, aiming for commercial and operational synergies that drive leadership in advanced regenerative wound care. (Link)
Halozyme Therapeutics (NASD: HALO) completes $750 Million Acquisition of Elektrofi, Unlocks Hypercon™ Technology for High-Concentration Biologics and Expands Drug Delivery Offerings Hypercon™ enables highly concentrated biologics to be delivered subcutaneously, improving patient convenience and supporting at-home care. Halozyme Therapeutics will pursue royalty-based licensing for products built on Elektrofi’s technology, with expected milestone payments and clinical launches that could begin driving revenues and broader market impact starting in 2030. (Link)
Nanox Imaging (NASD: NNOX) to acquire VasoHealthcare IT from Vaso Corporation (OTCQX: VASO) for Up to $800,000 to Accelerate U.S. Rollout of FDA-Cleared AI Medical Imaging Solutions Nanox’s platform brings real-time AI analysis and automated detection to routine CT imaging, offering multiple FDA-cleared solutions for radiology and cardiology. The acquisition leverages VasoHealthcare IT’s healthcare relationships for broader market coverage, enabling faster hospital adoption and improved integration of AI-driven workflows for earlier chronic disease identification. (Link)
RadNet (NASD: RDNT) acquires River Radiology, Strengthening New York Imaging Network and Expanding Lenox Hill Radiology’s Geographic Reach River Radiology’s Kingston facility delivers patient-centered care with advanced imaging services such as MRI, CT, PET/CT, 3D mammography, and ultrasound. Extended weekday hours and flexible scheduling support provider referrals. Its reputation for accurate reports, innovative screening, and compassionate service has defined medical imaging excellence across the Hudson Valley region. (Link)
ClearPoint Neuro (NASD: CLPT) completes acquisition of IRRAS, Bringing IRRAflow System and Expanding Neurocritical Care and Drug Delivery Capabilities IRRAflow uses active irrigation and drainage to effectively treat brain haemorrhages, leading to faster clearance of blood, fewer catheter infections, and reduced risk of blockages compared to passive drains. Clinical studies report improved patient outcomes, shorter treatment duration, and lower hospital costs for those treated with this innovative technology. (Link)
Reliant Healthcare and Care Fusion Rx Merge to Transform U.S. Infusion Therapy with Expanded Home and Ambulatory Service Platform Reliant Healthcare operates 14 infusion centers and specialty pharmacies across the southern U.S., while Care Fusion Rx brings expertise in advanced therapies—including immunoglobulin treatments—for chronic and rare diseases. The merger will drive national expansion with new locations, broader coverage, and investment in patient-focused care guided by experienced leadership. (Link)
ARC Health Partners acquires Clarity Counselling Center, Adding Wilmington-Based Practice to 23-Group National Network and Expanding North Carolina Reach with Backing from Thurston Group Clarity Counselling Center offers therapy for individuals, couples, and families, specializing in anxiety, depression, trauma, ADHD, grief, and relationship issues in Wilmington, NC. Their team of over 13 therapists uses evidence-based therapies like CBT and DBT, ensuring client-therapist matching and personalized care for children, teens, and adults. (Link)
MRO acquires Clinetic, via its financial sponsors Healthworx and Parthenon Capital Partners to Transform Patient Recruitment and Streamline Clinical Trial Enrollment with Scalable AI-EHR Integration Clinetic’s software uses AI to analyse both structured and unstructured patient data for real-time matching to clinical studies, dramatically accelerating recruitment. By integrating with EHRs, it supports secure workflow automation, precise cohort building, and reduces site workload—expediting enrollment for a nationwide hospital network and the Q-Centrix Research Network. (Link)
OhioHealth, a Columbus-based nonprofit health system, is acquiring the independent 220-bed Fairfield Medical Center in Lancaster, OH. The deal will expand OhioHealth’s network to 17 hospitals and enhance regional care. The boards endorsed the merger in September 2024 after a non-binding letter of intent, with benefits including increased efficiencies, improved quality measures, and access to larger system resources for a growing population. Pending regulatory approvals and government filings, the deal is expected to close in 2026; no financial terms were disclosed. (Link)
WVU Health System to acquire Independence Health System, Growing to 30-Hospital Network with $800 Million Investment Commitment Morgantown-based WVU Health System will acquire Greensburg’s Independence Health System, including five hospitals, physician groups, and subsidiaries, rebranding under WVU Medicine. WVU pledges $800 million over five years for facility modernization. Closing anticipated in fall 2026. (Link)
Function Health raises $298 Million Series B led by Redpoint Ventures and a16z at $2.5 Billion valuation for Medical Intelligence Lab launch. Function Health offers comprehensive lab testing, body scans, and health data consolidation to detect over 1,000 conditions early via more than 100 biomarkers. The funding will expand U.S. locations, develop AI health features, and lower annual membership pricing. It also backs the Medical Intelligence Lab to advance health and longevity research for proactive care. (Link)
